Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognosis and treatment response stratification according to loss of proofreading (LOP) POLE variants.

Journal for immunotherapy of cancer - 18 Nov 2025

Maddalena Giulia, Zeineddine Fadl A, Chowdhury Saikat, Zeineddine Mohammad A, Yousef Abdelrahman M, Bergamo Francesca, Lonardi Sara, Yap Timothy A, White Michael Geoffrey, Overman Michael J, Kopetz Scott, Shen John Paul

Abstract excerpt

BACKGROUND: Only a subset of polymerase epsilon (POLE) mutations is associated with hypermutant phenotype; we hypothesized that only loss-of-proofreading (LOP) POLE mutations are associated with favorable immunotherapy response. METHODS: This retrospective cohort study included a pan-cancer cohort of 69,223 patients from cBioPortal and a cohort of patients with 41 POLE mutant metastatic colorectal (CRC) treated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Polymerase II

Share to Immunotherapy

Share to Mutation

Share to Neoplasms

Share to Poly-ADP-Ribose Binding Proteins

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 41253491
DOI: 10.1136/jitc-2025-012190
PMCID: PMC12636876

Genes

POLE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognosis and treatment response stratification according to loss of proofreading (LOP) POLE variants.PMID 41253491Read ↗

The clinical landscape of POLE-mutant colorectal cancer: a retrospective analysis of real-world outcome.Semantic proximity Read ↗

Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.Semantic proximity Read ↗

Immune checkpoint inhibitors in POLE/POLD1 proofreading-deficient CRC: from molecular basis to clinical practice and future directions.Semantic proximity Read ↗

Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers.Semantic proximity Read ↗

Clinicopathological and mutational analyses of colorectal cancer with mutations in the POLE geneSemantic proximity Read ↗

Phenotypic POLE Variant Classification Identifies Patients Who May Have Favorable Prognosis and Benefit from Immunotherapy.Semantic proximity Read ↗

Pathogenic POLE-Mutated Endometrial Carcinomas With a Nonultramutated Genome.Semantic proximity Read ↗

Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitorSemantic proximity Read ↗

Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to favorable survival of tumors with POLE mutations outside the exonuclease domainSemantic proximity Read ↗

Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer.Semantic proximity Read ↗

DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review.Semantic proximity Read ↗

The game-changing impact of POLE mutations in oncology—a review from a gynecologic oncology perspectiveSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.